School of Medicine and Institute for Life Sciences, South China University of Technology, Guangzhou, 510006, China.
School of Medicine and Institute for Life Sciences, South China University of Technology, Guangzhou, 510006, China.
Biomaterials. 2021 Apr;271:120720. doi: 10.1016/j.biomaterials.2021.120720. Epub 2021 Feb 14.
Point mutations within the DNA-binding domain of the TP53 gene occur in a significant percentage of human cancer, leading to cellular accumulation of highly stabilized mutant p53 proteins (mutp53) with tumor-promoting properties. Depletion of mutp53, through inducing either autophagic or proteasomal degradation, is an attractive strategy for the therapy of p53-mutated cancer, but the currently-known degradation inducers, almost exclusively small molecules, are inadequate. Here we show that pH-responsive zeolitic imidazolate framework-8 (ZIF-8) offers a novel solution to mutp53 degradation. ZIF-8 facilitated ubiquitination-mediated and glutathionylation-dependent proteasomal degradation of all of the nine mutp53 we tested, including six hot-spot mutp53, but not the wild-type p53 protein. Sustained elevation of intracellular Zn level, resulted from decomposition of the internalized ZIF-8 in the acidic endosomes, decreased the intracellular reduced glutathione (GSH): oxidized glutathione (GSSG) ratio and was essential for mutp53 glutathionylation and degradation. ZIF-8 modified with an Z1-RGD peptide, exhibiting enhanced cellular internalization and improved decomposition behavior, preferentially killed mutp53-expressing cancer cells and demonstrated remarkable therapeutic efficacy in a p53 S241F ES-2 ovarian cancer model as well as in a p53 Y220C patient-derived xenograft (PDX) breast cancer model. The ability to induce wide-spectrum mutp53 degradation gives ZIF-8 a clear advantage over other degradation-inducers, and engineered nanomaterials may be promising alternatives to small molecules for the development of mutp53-targeting drugs.
点突变发生在 DNA 结合域的 TP53 基因中的一个显著比例的人类癌症,导致细胞积累的高度稳定的突变 p53 蛋白(mutp53)具有促进肿瘤的特性。depletion mutp53,通过诱导自噬或蛋白酶体降解,是一种有吸引力的策略,治疗 p53 突变的癌症,但目前已知的降解诱导剂,几乎完全是小分子,是不够的。在这里,我们展示了 pH 响应沸石咪唑酯骨架-8(ZIF-8)提供了一个新的解决方案mutp53 降解。ZIF-8 促进泛素化介导和谷胱甘肽依赖的蛋白酶体降解我们测试的九个 mutp53 中的所有,包括六个热点 mutp53,但不是野生型 p53 蛋白。持续升高的细胞内锌水平,由于分解的内化 ZIF-8 在酸性内涵体,减少细胞内还原型谷胱甘肽(GSH):氧化型谷胱甘肽(GSSG)的比例是必不可少的 mutp53 谷胱甘肽化和降解。ZIF-8 修饰与 Z1-RGD 肽,表现出增强的细胞内化和改善分解行为,优先杀死 mutp53 表达的癌细胞,并表现出显著的治疗效果,在 p53 S241F ES-2 卵巢癌模型和 p53 Y220C 患者来源异种移植(PDX)乳腺癌模型。诱导广谱 mutp53 降解的能力使 ZIF-8 明显优于其他降解诱导剂,工程纳米材料可能是小分子替代物,用于开发 mutp53 靶向药物的有前途的替代品。